I am not sure if this video has already been posted by someone else on HC (this is one of the downsides I have to deal with for not being very active on HC as I miss many posts). If it has already been posted, then please accept my apologies.
Not since the CHF Phase 3 results have been released have I been this excited.NOTE: Video is at the bottom of this post.
I am actually super excited to hear Dr. Emerson Perin (he was the CHF trial's co-principal investigator) talk about the Phase 3 results in this video below.
The entire video is about an hour but Dr. Perin's section is roughly 30 minutes.
The video was produced by the Baker Institute for Policy Research and was published on 05/20/21. The interviewer is Dr. Kirsten Matthews, Fellow in Science and Technology Policy at the Baker Institute, which is a part of Rice University in Houston, TX.
What I particularly like is the fact that Dr. Perin speaks so highly of Mesoblast's CHF treatment, coming as a neutral outsider (as in not a Mesoblast employee).
On top of that, Dr. Kirsten Matthews focuses on ethical and policy issues related to biomedical research and development. Specifically, she is looking at
regulation and ethical issues related to emerging biotechnology, including genetics and stem cell therapies.You can start watching from the 11:00 mark.
NOTE:
Pay attention to Dr. Perin's body language when he talks about Mesoblast's treatment.
1. At the 17:00 minute mark, Dr. Perin says he is very excited about allogeneic stem cell therapy, as opposed to autologous, which he is not an advocate of. He lays out the disadvantages of autologous and prefers allogeneic stem cells.
2. At 22:00 he starts talking about Mesoblast's CHF
3. At 26:00 he describes the Phase 3 results. And this is what he says:
"
The efficacy of the treatment is best when giving the injection of cells upfront and the results of reduction in strokes and heart attacks are over a 5 year period"
"But I want to tell you this is now in the realm of, it's not an objective truth, we had so much to find out about this, but this is very objective evidence that really is something we go to the FDA with and that the FDA can then say "Oh, we see evidence if this, let's let then may be you turn this into an actual practical treatment""4. At the 28:00 mark, he says "....approval is now tangible.....we are very close to an approval for this treatment"
5. From the 52:50 to 54:05 mark, he talks about the immune response
6. From 55:30 to 57:45 he says:
"MSCs provide an amazing anti-inflammatory treatment in your body"
"Heart Failure is systemic inflammation"
"We are sitting on amazing datathat will become known pretty soon that I think will start changing some of the things we do in cardio-vascular medicine" (regarding Mesoblast CHF treatment)Folks, I have never doubted the CHF results. In fact, I have posted this back in December:
https://hotcopper.com.au/threads/ann-mesoblast-phase-3-chronic-heart-failure-results.5816627/page-796?post_id=49794317
In the above post, I mentioned Novartis' acquisition of The Medicines Company (for $9.7 billion for Inclisiran, an LDL-C lowering drug).
In my book, Mesoblast should be valued at at least $20 billion right now. At least.
PS: Opinions my own, please do not take anything I post as financial advice.
Enjoy your weekend folks!
@ChewingHands - thanks for your kind words. I do not post on yahoo. It's format sucks and half the time, stuff does not get uploaded anyway.
@andy25 - Mesoblast is a publicly listed company and silviu.itescu@mesoblast is not a private email. It's not like his google or yahoo email. You conveniently took things out of context from my previous post. If you read my posts, my agenda is clear to all. Do you not know that there is no IR people at Mesoblast? How else do you contact them? The generic email listed on their website is useless.
(20min delay)